In addition, compared to the mono-therapy, combination of Plk1 inhibition with anti-mitotic or DNA damage agents induces more severe mitotic defects followed by apoptosis, and inhibits more strongly proliferation of cancer cells with functional p53. This evidence concerns the gene PLK1 and cancer.